FDA Approves New Antiplatelet Drug for Patients Undergoing PCI

Share this content:
FDA Approves New Antiplatelet Drug for Patients Undergoing PCI
FDA Approves New Antiplatelet Drug for Patients Undergoing PCI

TUESDAY, June 23, 2015 (HealthDay News) -- Kengreal (cangrelor) has been approved by the U.S. Food and Drug Administration to prevent blood clots from forming during angioplasty.

The intravenous medication is approved for adult patients undergoing percutaneous coronary intervention. By preventing platelets from accumulating, Kengreal reduces the risk of serious clotting complications related to the procedure, including heart attack and stent thrombosis.

In clinical trials, Kengreal was compared to Plavix (clopidogrel) among more than 10,000 participants. Cases of serious bleeding, while still rare, were more common among users who took Kengreal than Plavix, the FDA said. As with any anti-clotting drug, life-threatening bleeding is a potential side effect, the agency noted.

"For patients undergoing percutaneous coronary intervention, blood clotting can cause serious problems," Norman Stockbridge, M.D., Ph.D., director of the Division of Cardiovascular and Renal Drugs in the FDA's Center for Drug Evaluation and Research, said in a statement. "The approval of Kengreal provides another treatment option for patients."

Kengreal is manufactured by The Medicines Co., based in Parsippany, N.J.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

Non-Nutritive Sweeteners Don't Up Blood Glucose Levels

Non-Nutritive Sweeteners Don't Up Blood Glucose Levels

Concentration of NNSs decreases gradually over the course of observation after consumption

Laws Allowing Service Denial to Sexual Minorities Tied to Distress

Laws Allowing Service Denial to Sexual Minorities Tied ...

Laws permitting denial of services linked to increase in mental distress among sexual minorities

Antidepressant Prescribing Linked to Lasting Weight Gain

Antidepressant Prescribing Linked to Lasting Weight Gain

Risk of weight gain remained increased during at least six years of follow-up